Hypercalcemia associated with cancer

New England Journal of Medicine

Volumn 352, Issue 4, 2005, Pages

  Stewart, Andrew F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; NITROGEN; PHOSPHORUS; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CALCIUM BLOOD LEVEL; CASE REPORT; CENTRAL VENOUS PRESSURE; CONFUSION; CREATININE BLOOD LEVEL; DEHYDRATION; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCALCEMIA; JUGULAR VEIN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

EID: 19944431791     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp042806     Document Type: Article

References (47)

1. Stewart AF, Broadus AE. Malignancy-associated hypercalcemia. In: DeGroot L, Jameson LJ, eds. Endocrinology. 5th ed. Philadelphia: Saunders (in press).
2. Horwitz MJ, Stewart AF. Humoral hypercalcemia of malignancy. In: Favus MF, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington D.C.: American Society for Bone and Mineral Research, 2003:246-50.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
4. Clines GA, Guise TA. Hypercalcemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington D.C.: American Society for Bone and Mineral Research, 2003:251-6.
5. Ralston SH, Gallagher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality: clinical experience in 126 treated patients. Ann Intern Med 1990;112:499-504.
6. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
7. Stewart AF, Vignery A, Silvergate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982;55:219-27.
8. Nakayama K, Fukumoto S, Takeda S, et al. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab 1996;81: 607-11.
9. Bonjour J-P, Philippe J, Guelpa G, et al. Bone and renal components in hypercalcemia of malignancy and response to a single infusion of clodronate. Bone 1988;9:123-30.
10. Horwitz MJ, Tedesco MB, Sereika SM Hollis BW, Garcia-Ocaña A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 2003;88: 1603-9.
11. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 1994;121:633-40.
12. Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 1990;323: 1324-8.
13. John R, Oleesky D, Issa B, et al. Pseudohypercalcaemia in two patients with IgM paraproteinaemia. Ann Clin Biochem 1997; 34:694-6.
14. Ladenson JH, Lewis JW, McDonald JM, Slatopolsky E, Boyd JC. Relationship of free and total calcium in hypercalcemic conditions. J Clin Endocrinol Metab 1978;48:393-7.
15. Stewart AF. Normal physiology of bone and mineral homeostasis. In: Andriole TE, ed. Cecil essentials of medicine. 5th ed. Philadelphia: Saunders, 2004:683-94.
16. LeBoff MS, Mikulec KH. Hypercalcemia: clinical manifestations, pathogenesis, diagnosis, and management. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington D.C.: American Society for Bone and Mineral Research, 2003:225-30.
17. Bilezikian JP, Silverberg SJ. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004;350:1746-51.
18. Godsall JW, Burtis WJ, Insogna KL, Broadus AE, Stewart AF. Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy. Recent Prog Horm Res 1986; 42:705-50.
19. Jara A, Lee E, Stauber D, Moatamed F, Felsenfeld AJ, Kleeman CR. Phosphate depletion in the rat: effect of bisphosphonates and the calcemic response to PTH. Kidney Int 1999;55:1434-43.
20. Lentz RD, Brown DM, Kjellstrand CM. Treatment of severe hypophosphatemia. Ann Intern Med 1978;89:941-4.
21. Goldsmith RS, Ingbar SH. Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 1966;274:1-7.
22. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
23. Cheer SM, Noble S. Zoledronic acid. Drugs 2001;61:799-805.
24. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993;95: 297-304.
25. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-90.
26. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 1999;14:1557-61.
27. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-67.
28. Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M, Bergstrom B. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003;11:539-47.
29. Ralston SH, Thiebaud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
30. Jacobs TP, Siris ES, Bilezikian JP, Bauiran DC, Shane E, Canfield RE. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 1981;94:312-6.
31. Shah S, Hardy J, Rees E, et al. Is there a dose-response relationship for clodronate in the treatment of tumor-induced hypercalcaemia? Br J Cancer 2002;86:1235-7.
32. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med 1982;72:221-6.
33. Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992;10:134-42.
34. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996;45: 175-9.
35. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. [Erratum, J Clin Oncol 2004;22:1351.]
36. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57. [Erratum, J Clin Oncol 2004;22:1351.]
37. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.
38. Binstock ML, Mundy GR. Effect of calcitonin and glucocorticoids in combination on the hypercalcemia of malignancy. Ann Intern Med 1980;93:269-72.
39. Watson L, Moxham J, Fraser P. Hydrocortisone suppression test and discriminant analysis in differential diagnosis of hypercalcaemia. Lancet 1980;1:1320-5.
40. Wisneski LA, Croom WP, Silva OL, Becker KL. Salmon calcitonin in hypercalcemia. Clin Pharmacol Ther 1978;24:219-22.
41. Perlia CP, Gubisch NJ, Wolter J, Edelberg D, Dederick MM, Taylor SG III. Mithramycin treatment of hypercalcemia. Cancer 1970;25:389-94.
42. Leyland-Jones B. Treatment of cancer-related hypercalcemia: the role of gallium nitrate. Semin Oncol 2003;30:Suppl 5:13-9.
43. Cardella CJ, Birkin BL, Rapoport A. Role of dialysis in the treatment of severe hypercalcemia: report of two cases successfully treated with hemodialysis and review of the literature. Clin Nephrol 1979;12:285-90.
44. Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996;72:424-8.
45. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001;16:348-60.
46. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled trial of AMG162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-66.
47. Saw K, Onuma E, Yocum RC, Ogata E. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 2003;30:Suppl 16: 167-73.